Altimmune Granted Fast Track Designation Vy FDA For Pemvidutide For Treatment Of Non-Alcoholic Steatohepatitis (NASH)
Portfolio Pulse from Benzinga Newsdesk
The FDA has granted Fast Track Designation to Altimmune for Pemvidutide, a treatment for Non-Alcoholic Steatohepatitis (NASH). This designation will expedite the development and review process for the drug.
October 26, 2023 | 11:32 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Altimmune's Pemvidutide has been granted Fast Track Designation by the FDA. This could potentially speed up the drug's development and review process, potentially leading to earlier market entry.
Fast Track Designation by the FDA is a significant regulatory milestone that can expedite the development and review process of a drug. This could potentially lead to earlier market entry for Pemvidutide, which would be beneficial for Altimmune. Therefore, this news is likely to have a positive impact on Altimmune's stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100